Mineralys Therapeutics (NASDAQ:MLYS) Director Daphne Karydas Sells 3,000 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Director Daphne Karydas sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $28.58, for a total transaction of $85,740.00. Following the sale, the director directly owned 6,200 shares of the company’s stock, valued at approximately $177,196. The trade was a 32.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mineralys Therapeutics Stock Up 1.6%

Shares of MLYS opened at $27.98 on Friday. The company has a market capitalization of $2.47 billion, a P/E ratio of -6.60 and a beta of 0.68. The company has a debt-to-equity ratio of 0.18, a current ratio of 34.46 and a quick ratio of 34.46. Mineralys Therapeutics, Inc. has a one year low of $22.30 and a one year high of $47.65. The business’s 50 day simple moving average is $27.13 and its 200-day simple moving average is $27.11.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.30). As a group, sell-side analysts predict that Mineralys Therapeutics, Inc. will post -4.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Jefferies Financial Group reissued a “hold” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Wall Street Zen cut shares of Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Friday, July 17th. Finally, Zacks Research raised shares of Mineralys Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, September 11th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $48.80.

Institutional Investors Weigh In On Mineralys Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in MLYS. KBC Group NV acquired a new position in shares of Mineralys Therapeutics during the first quarter valued at $33,000. Caitong International Asset Management Co. Ltd increased its position in Mineralys Therapeutics by 1,845.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company’s stock worth $76,000 after purchasing an additional 1,993 shares during the period. FNY Investment Advisers LLC raised its holdings in Mineralys Therapeutics by 400.0% during the 2nd quarter. FNY Investment Advisers LLC now owns 2,500 shares of the company’s stock worth $67,000 after purchasing an additional 2,000 shares during the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in Mineralys Therapeutics during the 4th quarter worth about $232,000. Finally, Capstone Investment Advisors LLC bought a new stake in Mineralys Therapeutics during the 2nd quarter worth about $226,000. 84.46% of the stock is owned by institutional investors and hedge funds.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney-related diseases. The company’s research is centered on conditions associated with excess aldosterone activity, including uncontrolled and resistant hypertension.

Mineralys’ lead investigational product is lorundrostat, also known as MLS-101, an oral, highly selective aldosterone synthase inhibitor. The company is evaluating lorundrostat in clinical studies as a potential treatment for patients whose blood pressure remains inadequately controlled despite existing therapy.